PharmaShots | Incisive News in 3 Shots

Subscribe Now

ObsEva

ObsEva’s Yselty (linzagolix) Receive EC's Marketing Authorization for the Treatment of Uterine Fibroids

ObsEva’s Yselty (linzagolix) Receive EC's Marketing Authorization for the Treatment of Uterine Fibroids

June 20, 2022

ObsEva Reports Efficacy Results of Linzagolix in the P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain

ObsEva Reports Efficacy Results of Linzagolix in the P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain

March 23, 2022

ObsEva Entered into a License Agreement with Theramex to Commercialize Linzagolix for Uterine Fibroids and Endometriosis -Associated Pain

ObsEva Entered into a License Agreement with Theramex to Commercialize Linzagolix for Uterine Fibroids and Endometriosis -Associat...

February 11, 2022

PharmaShots Weekly Snapshots (January 03 - 07, 2021)

PharmaShots Weekly Snapshots (January 03 - 07, 2021)

January 7, 2022

ObsEva Reports Results of Linzagolix in P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain

ObsEva Reports Results of Linzagolix in P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain

January 7, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us